Table2.

Reduction in Monthly Migraine Frequency and Intensity Over Time that Compares the Treatment Groups

	Cinnarizine (N = 20)	Topiramate (N = 20)
Prospective baseline period Migraine frequency, (per month) Mean$\pm$SD Migraine intensity, (per month) Mean $\pm$SD	8.0 $\pm$ 7.98 7.3 $\pm$ 2.12	7.5 $\pm$ 6.43 6.5 $\pm$ 2.42
After 4 weeks of double-blind phase Migraine frequency, (per month) Mean$\pm$SD P (vs. baseline) Migraine intensity, (per month) Mean $\pm$SD P (vs. baseline)	5.7 $\pm$ 5.70 0.007 5.6 $\pm$ 2.01 < 0.001	5.5 $\pm$ 6.02 0.008 5.3 $\pm$ 2.77 0.002
After 8 weeks of double-blind phase Migraine frequency, (per month) Mean$\pm$SD P (vs. baseline) Migraine intensity, (per month) Mean $\pm$SD P (vs. baseline)	4.5 $\pm$ 4.57 0.004 4.3 $\pm$ 2.15 < 0.001	3.9 $\pm$ 3.91 0.001 4.3 $\pm$ 2.62 < 0.001
After 12 weeks of double-blind phase Migraine frequency, (per month) Mean$\pm$SD P (vs. baseline) Migraine intensity, (per month) Mean $\pm$SD P (vs. baseline)	2.0 $\pm$ 2.47 0.001 2.6 $\pm$ 2.37 < 0.001	2.7 $\pm$ 3.26 0.001 3.5 $\pm$ 2.74 < 0.001

P values are measured using sample (paired) t test, from the comparison between baseline phase values and 4, 8, and 12 weeks of treatment during the double-blind phase values.